Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 1, 2013, Pages 9-17

  Maneiro, R J ^a   Salgado, Eva ^a   Carmona, Loreto ^a,b   Gomez Reino, Juan J ^a,c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Abatacept; Response; Rheumatoid factor; Rituximab; Tocilizumab

Indexed keywords

ABATACEPT; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN M; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TOCILIZUMAB;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL (TOPIC); EUROPE; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REGISTER; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW;

ABATACEPT; RESPONSE; RHEUMATOID FACTOR; RITUXIMAB; TOCILIZUMAB;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOCONJUGATES; RHEUMATOID FACTOR; TREATMENT OUTCOME;

EID: 84881558263     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2012.11.007     Document Type: Article

References (70)

1. Maini R., Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354(9194):1932-1939.
2. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50(5):1400-1411.
3. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363(9410):675-681.
4. Miriovsky B.J., Michaud K., Thiele G.M., O'Dell J.R., Cannon G.W., Kerr G., et al. Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis 2010, 69(7):1292-1297.
5. Bas S., Genevay S., Meyer O., Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003, 42(5):677-680.
6. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54(9):2793-2806.
7. Pyrpasopoulou A., Douma S., Triantafyllou A., Simoulidou E., Samara M., Parapanisiou E., et al. Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers. Mol Diagn Ther 2010, 14(1):43-48.
8. Roll P., Dorner T., Tony H.P. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008, 58(6):1566-1575.
9. Tsiakalos A.P., Avgoustidis N.K., Moutsopoulos H.M. Rituximab therapy in Greek patients with rheumatoid arthritis. Biologics 2008, 2(4):911-916.
10. Bobbio-Pallavicini F., Caporali R., Alpini C., Avalle S., Epis O.M., Klersy C., et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007, 66(3):302-307.
11. Klaasen R., Cantaert T., Wijbrandts C.A., Teitsma C., Gerlag D.M., Out T.A., et al. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study. Rheumatology (Oxford) 2011, 50(8):1487-1493.
12. Lequerre T., Jouen F., Brazier M., Clayssens S., Klemmer N., Menard J.F., et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. Rheumatology (Oxford) 2007, 46(3):446-453.
13. Hayden J.A., Cote P., Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006, 144(6):427-437.
14. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
15. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997, 315(7109):629-634.
16. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
17. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. Br Med J 2003, 327(7414):557-560.
18. Thompson S.G., Higgins J.P. How should meta-regression analyses be undertaken and interpreted?. Stat Med 2002, 21(11):1559-1573.
19. Burmester G.R., Feist E., Kellner H., Braun J., Iking-Konert C., Rubbert-Roth A. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011, 70(5):755-759.
20. Chatzidionysiou K., Lie E., Nasonov E., Lukina G., Hetland M.L., Tarp U., et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011, 70(9):1575-1580.
21. Haraoui B., Bokarewa M., Kallmeyer I., Bykerk V.P. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: The RESET trial. J Rheumatol 2011.
22. Kawashiri S.Y., Kawakami A., Iwamoto N., Fujikawa K., Aramaki T., Tamai M., et al. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol 2011, 21(4):370-374.
23. Quartuccio L., Fabris M., Salvin S., Atzeni F., Saracco M., Benucci M., et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2009, 48(12):1557-1559.
24. Solau-Gervais E., Prudhomme C., Philippe P., Duhamel A., Dupont-Creteur C., Legrand J.L., et al. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine 2011, 1.
25. Teng Y.K., Levarht E.W., Hashemi M., Bajema I.M., Toes R.E., Huizinga T.W., et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007, 56(12):3909-3918.
26. Faustini F., D'Antona G., Laria A., Peluso G., Tolusso B., Bosello S.L., et al. B-cell directed therapy in rheumatoid arthritis: predictive factors of efficacy and assessment of regeneration profile. Ann Rheum Dis 2009, 68(Suppl 3):440. [Abstract].
27. Ferraccioli G., Tolusso B., Bobbio-Pallavicini F., Gremese E., Ravagnani V., Benucci M., et al. Biomarkers predictors of good EULAR response to B cell depletion therapy (BCDT) in seropositive rheumatoid arthritis patients. Arthritis Rheum 2010, 62(Suppl 10):1098. [Abstract].
28. Gottenberg J.E., Ravaud P., Bardin T., Cantagrel A., Combe B., Dougados M., et al. Positivity for RF/anti-CCP is associated with a better response to abatacept: data from the "Orencia and Rheumatoid Arthritis" (ORA) registry. Ann Rheum Dis 2011, 70(Suppl 3):74. [Abstract].
29. Lopez-Gonzalez R., Sánchez-González M.D., Gømez-Castro S., Montilla-Morales C., Del Pino J. Is the rheumatoid factor or concomitant treatment for the rheumatoid arthritis responsible of the rituximab response?. Ann Rheum Dis 2010, 69(Suppl 3):683. [Abstract].
30. Peluso G., Faustini F., Gremese E., D'Antona G., Laria A., Tolusso B., et al. B-cell depletion in rheumatoid arthritis: searching for serologic and clinical baseline factors that could predict long-term efficacy. Ann Rheum Dis 2010, 69(Suppl 3):683. [Abstract].
31. Tony H.P., Roll P., Mei H.E., Gnuegge L., Kobialko M., Dörner T., et al. Predictive factors for response to Rituximab in patients with rheumatoid arthritis (FIRST). Ann Rheum Dis 2011, 70(Suppl 3):292. [Abstract].
32. Assous N., Gossec L., Dieude P., Meyer O., Dougados M., Kahan A., et al. Rituximab therapy in rheumatoid arthritis in daily practice. J Rheumatol 2008, 35(1):31-34.
33. Belmonte Serrano M.A., Pincus T. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2010, 49(9):1795-1796. [author reply 6-7].
34. Benucci M., Manfredi M., Puttini P.S., Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?. Autoimmun Rev 2010, 9(12):801-803.
35. Bokarewa M., Lindholm C., Zendjanchi K., Nadali M., Tarkowski A. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy. Scand J Immunol 2007, 66(4):476-483.
36. Cambridge G., Leandro M.J., Edwards J.C.W., Ehrenstein M.R., Salden M., Bodman-Smith M., et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis and Rheumatism 2003, 48(8):2146-2154.
37. Emery P., Deodhar A., Rigby W.F., Isaacs J.D., Combe B., Racewicz A.J., et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010, 69(9):1629-1635.
38. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 5:1390-1400.
39. Fabris M., de Vita S., Blasone N., Visentini D., Pezzarini E., Pontarini E., et al. Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF iga in the follow-up of patients with rheumatoid arthritis treated with rituximab. Autoimmun Highlights 2010, 1(2):87-94.
40. Genovese M.C., Becker J.C., Schiff M., Luggen M., Sherrer Y., Kremer J., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor a inhibition. N Eng J Med 2005, 11:1114-1123.
41. Gibbons L.J., Hyrich K.L. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response. BioDrugs 2009, 23(2):111-124.
42. Iking-Konert C., Aringer M., Wollenhaupt J., Mosch T., Tuerk S., Feist E., et al. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann Rheum Dis 2011, 70(11):1986-1990.
43. Jois R.N., Masding A., Somerville M., Gaffney K. Scott DGI. Rituximab therapy in patients with resistant rheumatoid arthritis: Real-life experience. Rheumatology 2007, 46(6):980-982.
44. Khan A., Scott D. Rituximab after methotrexate failure in rheumatoid arthritis: evaluation of the SERENE trial. Expert Opin Biol Ther 2011, 11(11):1515-1518. Nov.
45. Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Takagi H, et al. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. Mod Rheumatol 2011[Sep 20].
46. Kormelink T.G., Tekstra J., Thurlings R.M., Boumans M.H., Vos K., Tak P.P., et al. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann Rheum Dis 2010, 69(12):2137-2144.
47. Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int 2010 [May 16].
48. Leffers H.C., Ostergaard M., Glintborg B., Krogh N.S., Foged H., Tarp U., et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011, 70(7):1216-1222.
49. McGonagle D., Tan A.L., Madden J., Taylor L., Emery P. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology (Oxford) 2008, 47(6):865-867.
50. Miriovsky B.J., Michaud K., Thiele G.M., O'Dell J.R., Cannon G.W., Kerr G., et al. Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis 2010, 69(7):1292-1297.
51. Quartuccio L., de Vita S. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology 2010, 49(9):1796-1797. [Reply, Letter (keq142)].
52. Quartuccio L., Salvin S., Saracco M., Lombardi S., Fabris M., Mansutti E., et al. [Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFalpha agents failed are associated with response to rituximab in rheumatoid arthritis]. Reumatismo 2009, 61(3):182-186.
53. Rooney T., Roux-Lombard P., Veale D.J., FitzGerald O., Dayer J.M., Bresnihan B. Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. Ann Rheum Dis 2010, 4:706-714.
54. Sellam J., Hendel-Chavez H., Rouanet S., Abbed K., Combe B., Le Loet X., et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011, 63(4):933-938.
55. Thurlings R.M., Vos K., Wijbrandts C.A., Zwinderman A.H., Gerlag D.M., Tak P.P. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008, 67(7):917-925.
56. Valleala H., Korpela M., Mottonen T., Hienonen-Kempas T., Kauppi M., Hannonen P., et al. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients. Scand J Rheumatol 2009, 38(5):323-327.
57. Yamanaka H., Tanaka Y., Inoue E., Hoshi D., Momohara S., Hanami K., et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 2011, 21(2):122-133.
58. Department of Health & Human Services. Food & Drug Administration. Briefing Document for the Arthritis Advisory Committee Meeting. Actemra®/Tocilizumab BLA 125276. 2008; 3-7]. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4371b1-01-FDA.pdf.
59. Jones G., Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2010, 3:81-89.
60. Kremer J.M., Dougados M., Emery P., Durez P., Sibilia J., Shergy W., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase Iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52(8):2263-2271.
61. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008, 67(8):1096-1103.
62. Dougados M., Gaillez C., Le Bars M., Poncet M., Elegbe A., Clinical M.S. Efficacy of Abatacept and Infliximab in Combination with Methotrexate According to Baseline Rheumatoid Factor Status in the ATTEST Trial. Rev Rhum Ed Fr 2011, 78(Suppl 5):A301. [Abstract number Me.112].
63. Sibilia J., Cantagrel A., Flipo R.M., Westhovens R., Gaillez C., Le Bars M., et al. Abatacept plus MTX treatment confers similar clinical efficacy in rheumatoid factor negative and positive patients in the AIM trial. Rev Rhum Ed Fr 2011, 78(Suppl 5):A300. [Abstract number Me.110].
64. Salgado E., Maneiro J.R., Carmona L., Gomez-Reino J.J. Influence of baseline rheumatoid factor on the response to tumor necrosis factor antagonists of rheumatoid arthritis patients: a systematic review and meta-analysis. Arthritis Rheum 2011, 63(Suppl 10):1197.
65. Illei G.G., Shirota Y., Yarboro C.H., Daruwalla J., Tackey E., Takada K., et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010, 62(2):542-552.
66. Nishimoto N., Kanakura Y., Aozasa K., Johkoh T., Nakamura M., Nakano S., et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005, 106(8):2627-2632.
67. Roll P., Muhammad K., Schumann M., Kleinert S., Einsele H., Dorner T., et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis Rheum 2011, 63(5):1255-1264.
68. Snir A., Kessel A., Haj T., Rosner I., Slobodin G., Toubi E. Anti-IL-6 receptor antibody (tocilizumab): a B cell targeting therapy. Clin Exp Rheumatol 2011, 29(4):697-700.
69. Wells G., Becker J.C., Teng J., Dougados M., Schiff M., Smolen J., et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009, 68(6):954-960.
70. Jones G., Sebba A., Gu J., Lowenstein M.B., Calvo A., Gomez-Reino J.J., et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010, 69(1):88-96.